[{"id":"411c6656-9452-41f8-a0dc-a43d6083250d","acronym":"KEYNOTE-A91","url":"https://clinicaltrials.gov/study/NCT04701476","created_at":"2021-01-19T20:50:41.794Z","updated_at":"2024-07-02T16:35:36.295Z","phase":"Phase 2","brief_title":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","source_id_and_acronym":"NCT04701476 - KEYNOTE-A91","lead_sponsor":"Teclison Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • Tirazone (tirapazamine)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-21"}]